1. Home
  2. ORBS vs CLLS Comparison

ORBS vs CLLS Comparison

Compare ORBS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eightco Holdings Inc.

ORBS

Eightco Holdings Inc.

HOLD

Current Price

$0.76

Market Cap

447.0M

Sector

N/A

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$0.95

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORBS
CLLS
Founded
1966
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
447.0M
394.4M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
ORBS
CLLS
Price
$0.76
$0.95
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $4.83
AVG Volume (30 Days)
★ 14.9M
93.8K
Earning Date
11-13-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $31,820,779.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.70
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.88
52 Week High
$7.17
$5.45

Technical Indicators

Market Signals
Indicator
ORBS
CLLS
Relative Strength Index (RSI) 37.63 21.98
Support Level $0.74 N/A
Resistance Level $0.92 $2.99
Average True Range (ATR) 0.07 0.09
MACD -0.02 0.03
Stochastic Oscillator 17.09 15.95

Price Performance

Historical Comparison
ORBS
CLLS

About ORBS Eightco Holdings Inc.

Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: